Item 5.07. Submission of Matters to a Vote of Security Holders.

Aadi Bioscience, Inc. (the "Company") held its annual meeting of stockholders on June 14, 2022 (the "Annual Meeting"). At the Annual Meeting, 15,099,527 shares of the Company's common stock, representing approximately 72% of the voting power of all issued and outstanding shares of common stock of the Company as of April 20, 2022, the record date for the Annual Meeting, and constituting a quorum for the transaction of business, were present in person or by proxy and considered and voted on the following proposals, each of which is described in more detail in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 26, 2022: (1) the election of two Class II directors for terms to expire at the Company's 2025 annual meeting of stockholders and until their respective successors have been duly elected and qualified; and (2) the ratification of the appointment of BDO USA LLP as the Company's independent registered public accounting firm for the current fiscal year ending December 31, 2022.



Proposal 1: Election of two Class II directors to serve until the 2025 Annual
Meeting of Stockholders and until their respective successors have been elected
or qualified.

                                                     Broker
Director                For          Withheld       Non-Votes
Anupam Dalal          11,291,829       454,197       3,353,501
Karin Hehenberger     11,726,212        19,814       3,353,501

Proposal 2: Ratification of the appointment of BDO USA LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.



   For       Against   Abstentions
15,019,683   66,252      13,592

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses